Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the treatment of addiction and serious mental illnesses. The company's business model centers on the development, manufacture, and commercialization of buprenorphine-based prescription drugs and other therapies for opioid use disorder (OUD) and overdose reversal. Indivior's flagship product is Sublocade, a once-monthly extended-release buprenorphine injection that serves as its primary growth driver, alongside its legacy Suboxone sublingual film. The company also markets Opvee, a nalmefene nasal spray for opioid overdose reversal, and Perseris, a long-acting injectable for schizophrenia. Geographically, Indivior is heavily weighted toward the United States, which accounts for over 80% of its net revenue, with the remainder generated in Europe, Canada, Australia, and other international markets. The company's strategy focuses on shifting its revenue mix toward higher-growth, long-acting injectable therapies while expanding its addiction-science pipeline through selective business development, such as its 2023 acquisition of Opiant Pharmaceuticals. Competitively, Indivior holds a strong position in the OUD market due to its specialized operating capabilities, extensive clinical evidence, and established relationships with prescribers, treatment centers, and public-health channels, though it faces ongoing generic competition for its legacy oral products.
